Michael Schorr
General Practice · Patterson, CANPI 1508922089
Payments from drug & device makers
Across 247 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$668
- AstraZeneca$654
- AbbVie$483
- GSK$351
- Boehringer Ingelheim$326
- Lilly USA, LLC$199
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,613100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 39 | $668 |
| AstraZeneca | 26 | $654 |
| AbbVie(2 entities) | 30 | $483 |
| GSK | 19 | $351 |
| Boehringer Ingelheim | 18 | $326 |
| Lilly USA, LLC | 10 | $199 |
| Sanofi-aventis U.S. LLC | 12 | $185 |
| Novartis | 9 | $184 |
| Merck | 8 | $151 |
| Novo Nordisk | 8 | $140 |
| Amarin Pharma, Inc. | 5 | $138 |
| Otsuka America Pharmaceutical, Inc. | 8 | $136 |
| Teva Pharmaceuticals USA, Inc. | 7 | $116 |
| Amgen | 5 | $104 |
| Xeris Pharmaceuticals, Inc. | 5 | $96 |
| Johnson & Johnson | 5 | $87 |
| Baxter Healthcare | 3 | $73 |
| Eisai Inc. | 5 | $72 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Bayer | 2 | $43 |
| Biodelivery Sciences International, Inc. | 3 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| Corcept Therapeutics | 1 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Dexcom, Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Indivior Inc. | 1 | $24 |
| Smith+Nephew | 1 | $20 |
| Akebia Therapeutics Inc | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- VRAYLAR$108
How this compares
$4,613 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $121,169 |
| JardianceEmpagliflozin | 128 | $114,768 |
| EliquisApixaban | 71 | $56,082 |
| FarxigaDapagliflozin Propanediol | 54 | $38,354 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $35,841 |
| JanuviaSitagliptin Phosphate | 42 | $31,130 |
| XareltoRivaroxaban | 49 | $29,989 |
| TrulicityDulaglutide | 19 | $29,281 |
| LinzessLinaclotide | 22 | $16,095 |
| KerendiaFinerenone | 15 | $13,851 |
| TradjentaLinagliptin | 17 | $12,454 |
| Spiriva RespimatTiotropium Bromide | 20 | $9,757 |
| Atorvastatin Calcium | 644 | $8,066 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,233 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $326 | $136,979165 claims |
| Novo NordiskOzempic | $140 | $121,169132 claims |
| PfizerEliquis | $668 | $56,08271 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $654 | $50,42188 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $351 | $42,28970 claims |
| MerckJanuvia | $151 | $31,13042 claims |
| Johnson & JohnsonXarelto | $87 | $29,98949 claims |
| Lilly USA, LLCTrulicity | $199 | $29,28119 claims |
| AbbVieLinzess | $483 | $16,09522 claims |
| BayerKerendia | $43 | $13,85115 claims |
| Sanofi-aventis U.S. LLCLantus | $185 | $2,15526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Patterson
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.